Hamilton Quality · Independent Analysis
Consequential U.S. pharmaceutical and medical-device quality developments, translated into practical questions for the work ahead.
Current Brief
Independent commentary on publicly available enforcement actions, recalls, and regulatory developments.
This was not a quiet week for pharmaceutical and medical-device quality. The strongest developments involved retrospective OOS review, visible particulate investigations, packaging-control recurrence, sterile compounding and the effectiveness of device CAPA systems.
Several of the week’s enforcement actions also reinforce a common regulatory expectation: rejecting a batch, recalling a product or opening a CAPA does not complete an investigation. Firms must determine what happened, establish the affected population, evaluate distributed-product risk and demonstrate that their corrective actions address the underlying system.
Briefing Archive
Browse every issue online or keep a PDF copy for reference.
The week was moderately active but highly concentrated. FDA’s Warning Letter to Bausch + Lomb is the clear headline and belongs in any current reference file addressing contamination investigations, adverse trending and sterile-product disposition.
This week’s quality signal was concentrated but consequential: an FDA Warning Letter describing repeated CGMP observations, unfulfilled remediation commitments, and inadequate executive-management oversight; an injectable-drug recall demonstrating the importance of API-level product bounding; and several device actions involving correction effectiveness, software controls, recurrence analysis, and machine-learning validation.
Hamilton Quality helps teams turn quality signals into sound investigations and lasting corrective action.